Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs Invesco Galaxy Bitcoin ETF (BTCO) Price & Performance

Amgen, Inc.Trade
Invesco Galaxy Bitcoin ETFTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Invesco Galaxy Bitcoin ETF — how do they compare? Amgen, Inc. trades at $416.97 (market cap $224.14B), while Invesco Galaxy Bitcoin ETF trades at $63. The key difference: Amgen, Inc. pays a 2.43% dividend while Invesco Galaxy Bitcoin ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Invesco Galaxy Bitcoin ETF nearer its low. Which is the better fit depends on your goals.

AMGNBTCO
Market Cap
$224.14B
Sector
HealthCrypto-linked
52-Week High
$417.20$125.14
52-Week Low
$271.18$58.40
Enterprise Value
$267.45B
Dividend Yield
2.43%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.

Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.

Invesco Galaxy Bitcoin ETF

BTCO shares trade at $63.00, down 0.97% with technical indicators showing a bullish bias despite mixed signals. The stock faces resistance at $65 with support at $64, while moving averages suggest upward momentum. Recent market sentiment reflects cautious optimism amid broader financial market volatility.

The stock's outlook remains uncertain with technical strength countered by fundamental data gaps. Investment opportunity hinges on upcoming financial disclosures, while risks include market volatility and competitive pressures in the company's sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About Invesco Galaxy Bitcoin ETF

BTCO is a spot Bitcoin ETF that tracks the price of Bitcoin directly. It offers investors a regulated and convenient way to gain exposure to the digital currency through a traditional brokerage account without holding the asset.

Read more on BTCO